CoChat

The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia

Open access
Bhattacherjee, Abhishek, Jung, Jaesoo, Zia, Sameera, Ho, Madelene, Eskandari-Sedighi, Ghazaleh, St. Laurent, Chris D., McCord, Kelli A., Bains, Arjun, Sidhu, Gaurav, Sarkar, Susmita, Plemel, Jason R., Macauley, Matthew S. · 2021 · Molecular Neurodegeneration
Cited by 75

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Background: CD33 is genetically linked to Alzheimer’s disease (AD) susceptibility through differential expression of isoforms in microglia. The role of the human CD33 short isoform (hCD33m), preferentially encoded by an AD-protective CD33 allele (rs12459419T), is unknown. Here, we test whether hCD33m represents a loss-of-function or gain-of-function variant. Methods: We have developed two models to test the role of hCD33m. The first is a new strain of transgenic mice expressing hCD33m in the microglial cell lineage. The second is U937 cells where the CD33 gene was disrupted by CRISPR/Cas9 and complemented with different variants of hCD33. Primary microglia and U937 cells were tested in phagocytosis assays and single cell RNA sequencing (scRNAseq) was carried out on the primary microglia. Furthermore, a new monoclonal antibody was developed to detect hCD33m more efficiently. Results: In both primary microglia and U937 cells, we find that hCD33m enhances phagocytosis. This contrasts with the human CD33 long isoform (hCD33M) that represses phagocytosis, as previously demonstrated. As revealed by scRNAseq, hCD33m+ microglia are enriched in a cluster of cells defined by an upregulated expression and gene regulatory network of immediate early genes, which was further validated within microglia in situ. Using a new hCD33m-specific antibody enabled hCD33m expression to be examined, demonstrating a preference for an intracellular location. Moreover, this newly discovered gain-of-function role for hCD33m is dependent on its cytoplasmic signaling motifs, dominant over hCD33M, and not due to loss of glycan ligand binding. Conclusions: These results provide strong support that hCD33m represents a gain-of-function isoform and offers insight into what it may take to therapeutically capture the AD-protective CD33 allele.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-021-00443-6

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 75

Metadata

Authors
Bhattacherjee, A., Jung, J., Zia, S., Ho, M., Eskandari-Sedighi, G., St. Laurent, C. D., McCord, K. A., Bains, A., Sidhu, G., Sarkar, S., Plemel, J. R., & Macauley, M. S.
Venue
Molecular Neurodegeneration
Published
2021-03-25
Volume
16
Issue
1
Pages
19-19
ISSN
1750-1326 (ISSN-L)
OpenAlex
W3136938866
Cited by
75
References
33
FWCI
4.45
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia. https://app.cochat.ai/papers/10.1186/s13024-021-00443-6
The paper
Bhattacherjee, A., Jung, J., Zia, S., Ho, M., Eskandari-Sedighi, G., St. Laurent, C. D., McCord, K. A., Bains, A., Sidhu, G., Sarkar, S., Plemel, J. R., & Macauley, M. S. (2021). The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-021-00443-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.